Rosalind Advisors Inc. Has $11.58 Million Stock Position in Abeona Therapeutics Inc (NASDAQ:ABEO)

Rosalind Advisors Inc. grew its holdings in Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 4.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,832,000 shares of the biopharmaceutical company's stock after acquiring an additional 82,000 shares during the period. Abeona Therapeutics comprises approximately 7.3% of Rosalind Advisors Inc.'s holdings, making the stock its 4th biggest holding. Rosalind Advisors Inc. owned about 4.47% of Abeona Therapeutics worth $11,578,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Western Standard LLC grew its position in shares of Abeona Therapeutics by 68.5% in the 1st quarter. Western Standard LLC now owns 1,361,489 shares of the biopharmaceutical company's stock worth $9,871,000 after acquiring an additional 553,377 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Abeona Therapeutics by 581.6% during the 2nd quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company's stock valued at $2,134,000 after purchasing an additional 429,456 shares in the last quarter. Simplify Asset Management Inc. acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at $1,732,000. abrdn plc grew its stake in shares of Abeona Therapeutics by 158.8% in the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company's stock worth $2,067,000 after purchasing an additional 200,647 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Abeona Therapeutics by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company's stock valued at $515,000 after purchasing an additional 2,434 shares during the last quarter. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ABEO has been the subject of a number of recent analyst reports. StockNews.com raised shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, September 10th. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research report on Thursday, October 31st. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $18.00 price target on shares of Abeona Therapeutics in a report on Tuesday, October 29th.

Abeona Therapeutics Trading Up 1.1 %

ABEO stock traded up $0.07 during midday trading on Wednesday, hitting $6.28. 183,769 shares of the company's stock were exchanged, compared to its average volume of 433,637. Abeona Therapeutics Inc has a one year low of $3.05 and a one year high of $9.01. The stock's fifty day moving average price is $6.08 and its 200-day moving average price is $5.12. The company has a market cap of $272.01 million, a PE ratio of -2.44 and a beta of 1.52. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.48 and a current ratio of 7.48.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.42). Research analysts predict that Abeona Therapeutics Inc will post -1.28 earnings per share for the current fiscal year.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.